Johnson & Johnson
(JNJ)
Add Watchlist
154.64 USD +0.58
Closed: 17 May, 3:55 pm
Symbol JNJ
Market Cap 372.1B
Price 154.64
Open 154.86
52-wk High 175.97
50 Day Avg 152.41
Earnings Announcement 2024-07-17
Website https://www.jnj.com
Name Johnson & Johnson
Shares Outstanding 2,406,680,000
Change % 0.2333%
Low 153.71
52-wk Low 143.13
200 Day Avg 157.00
Last Dividend 4.96
Exchange NYSE
Volume 4,251,699
Previous Close 154.28
High 154.86
EPS 6.73
PE 22.98
Avg Volume 7,470,704
CUSIP 478160104
Johnson & Johnson Outlook
Description Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Currency USD
ISIN US4781601046
Industry Drug Manufacturers - General
Changes 0.36
CUSIP 478160104
Range 143.13 - 175.97
Beta 0.55
CIK 0000200406

Johnson & Johnson News

17-May-2024 5:21 PM

J&J-backed startup Rapport files for US IPO

Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson , filed for an initial public offering in the United States on Friday.

17-May-2024 1:01 PM

J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition

Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.

17-May-2024 7:11 AM

7 Value Stocks to Buy and Hold for a Decade of Dominance

Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment.

17-May-2024 6:30 AM

3 Cheap Healthcare Stocks to Buy Now: May 2024

With the market rally broadening out, value sectors are beginning to catch a bid. Healthcare deserves consideration as one of the value sectors presenting some bargains in this overheating market.

16-May-2024 12:50 PM

7 Upcoming Dividend Increases Including A King

Johnson & Johnson extends its 62-year streak of dividend increases with a 4.2% annual increase. Other companies on the list have streaks ranging from 7 to 21 years, with an average increase of 6.3%. The article provides a list of top-performing stocks likely to boost their dividends soon for smart investment choices.

16-May-2024 12:36 PM

Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

16-May-2024 11:42 AM

Ex-Dividend Reminder: Nuvei, Walgreens And Johnson & Johnson

On 5/20/24, Nuvei, Walgreens Boots Alliance, and Johnson & Johnson will all trade ex-dividend for their respective upcoming dividends. Nuvei will pay its quarterly dividend of $0.10 on 6/6/24, Walgreens Boots Alliance will pay its quarterly dividend of $0.25 on 6/12/24, and Johnson & Johnson will pay its quarterly dividend of $1.24 on 6/4/24.

16-May-2024 7:40 AM

Johnson & Johnson to acquire Proteologix for $850 million

Johnson & Johnson on Thursday said it would acquire privately held Proteologix for $850 million in cash, with potential for an additional milestone payment.

16-May-2024 7:30 AM

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with potential for an additional milestone payment. Proteologix's portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to seve.

16-May-2024 6:30 AM

Consumer Staples Standouts: 3 Defensive Gems to Safeguard Your Portfolio

After covering essentials, consumers spend on discretionary items. But it's the consumer staples items that make up the essential part of any budget.

14-May-2024 8:13 PM

Johnson & Johnson (JNJ) Management Presents at BofA Securities Health Care Conference (Transcript)

Johnson & Johnson (NYSE:JNJ ) BofA Securities Health Care Conference Transcript May 14, 2024 4:40 PM ET Executives John Reed - Executive Vice President, Innovative Medicine, R&D Analysts Geoff Meacham - Bank of America Charlie Yang - Bank of America Geoff Meacham The afternoon sessions of the first day of the BofA Healthcare Conference. My name is Geoff Meacham, I'm the Senior Biopharma Analyst here at BofA.